First Trust Advisors LP Raises Stock Holdings in ADMA Biologics Inc $ADMA

Key Points

• Institutional ownership increased: First Trust Advisors raised its ADMA Biologics stake by 1,361.1% to 360,217 shares, while institutional investors collectively own 75.68% of the company.
• Quarterly results were broadly positive: ADMA matched EPS expectations at $0.16, generated $124.4 million in revenue, and reported strong ASCENIV growth. Management maintained 2026 revenue guidance of $530 million to $560 million and is targeting more than $200 million in share repurchases.
• Risks remain: Revenue slightly missed estimates due to continued BIVIGAM weakness, Zacks downgraded the stock to “strong sell,” and the company faces securities-fraud litigation allegations that have not been established in court.

First Trust Advisors LP boosted its position in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 1,361.1% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 360,217 shares of the biotechnology company's stock after buying an additional 335,564 shares during the quarter. First Trust Advisors LP owned approximately 0.15% of ADMA Biologics worth $3,246,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Royal Bank of Canada increased its position in shares of ADMA Biologics by 112.7% in the first quarter. Royal Bank of Canada now owns 95,885 shares of the biotechnology company's stock valued at $1,903,000 after acquiring an additional 50,801 shares during the period. Ashton Thomas Private Wealth LLC purchased a new stake in shares of ADMA Biologics during the first quarter worth about $217,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of ADMA Biologics by 59.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 816,590 shares of the biotechnology company's stock worth $16,201,000 after purchasing an additional 305,064 shares during the last quarter. Norges Bank bought a new stake in shares of ADMA Biologics in the second quarter worth about $549,000. Finally, EverSource Wealth Advisors LLC grew its stake in shares of ADMA Biologics by 385.8% in the second quarter. EverSource Wealth Advisors LLC now owns 2,745 shares of the biotechnology company's stock worth $50,000 after purchasing an additional 2,180 shares during the last quarter. Hedge funds and other institutional investors own 75.68% of the company's stock.

ADMA Biologics Price Performance

Shares of NASDAQ ADMA opened at $10.06 on Friday. ADMA Biologics Inc has a 1 year low of $7.21 and a 1 year high of $20.46. The stock has a market capitalization of $2.33 billion, a P/E ratio of 14.37 and a beta of 0.74. The company's 50-day moving average is $8.59 and its 200 day moving average is $11.32. The company has a debt-to-equity ratio of 0.51, a current ratio of 6.95 and a quick ratio of 3.93.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.16 EPS for the quarter, hitting the consensus estimate of $0.16. The business had revenue of $124.39 million during the quarter, compared to analyst estimates of $125.34 million. ADMA Biologics had a net margin of 32.98% and a return on equity of 39.60%. ADMA Biologics's quarterly revenue was up 2.0% compared to the same quarter last year. During the same period last year, the business posted $0.14 earnings per share. On average, sell-side analysts expect that ADMA Biologics Inc will post 0.8 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have commented on ADMA. Raymond James Financial started coverage on ADMA Biologics in a research report on Wednesday, June 10th. They set an "outperform" rating and a $21.00 price target for the company. Zacks Research lowered ADMA Biologics from a "hold" rating to a "strong sell" rating in a research report on Tuesday. Wall Street Zen cut ADMA Biologics from a "buy" rating to a "hold" rating in a research note on Monday, May 4th. Mizuho decreased their target price on ADMA Biologics from $20.00 to $17.00 and set an "outperform" rating for the company in a report on Wednesday, July 15th. Finally, Canaccord Genuity Group dropped their price target on ADMA Biologics from $21.00 to $18.00 and set a "buy" rating for the company in a research note on Thursday, May 7th. Three analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $18.67.

Key Headlines Impacting ADMA Biologics

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: Strong earnings and ASCENIV growth: Second-quarter adjusted EPS of $0.16 matched consensus, while revenue reached $124.4 million. ASCENIV revenue rose 24% year over year to $102.9 million, GAAP net income increased 11% to $37.8 million, and adjusted EBITDA grew 22% to $61.8 million. ADMA Biologics Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Guidance maintained and buybacks planned: ADMA reiterated its 2026 revenue outlook of $530 million to $560 million, broadly consistent with analyst expectations, and is targeting more than $200 million in share repurchases. Management said accelerating ASCENIV demand should offset continued weakness in BIVIGAM. ADMA Reiterates 2026 Guidance and Share Repurchase Target
• Neutral Sentiment: BIVIGAM remains a concern: Quarterly revenue slightly missed expectations, at $124.4 million versus approximately $125.3 million expected, as BIVIGAM demand remained under pressure despite sequential stabilization. The company’s outlook assumes ASCENIV growth will compensate for that weakness. ADMA Q2 Earnings Meet, Revenues Miss on BIVIGAM Weakness
• Negative Sentiment: Legal overhang intensifies: Multiple law firms publicized a securities-fraud class action and an August 10 lead-plaintiff deadline for investors who bought shares between August 9, 2024, and March 25, 2026. The complaints allege misrepresentations involving financial condition, revenue recognition, inventory distribution, and business practices; these allegations have not been established in court. ADMA Investor Alert
• Negative Sentiment: Analyst downgrade: Zacks Research downgraded ADMA from “hold” to “strong sell,” adding pressure to sentiment even though the company met EPS expectations and maintained its outlook.

Insider Activity

In other news, Director Jerrold B. Grossman bought 12,500 shares of the stock in a transaction dated Monday, May 11th. The stock was bought at an average price of $8.01 per share, for a total transaction of $100,125.00. Following the purchase, the director directly owned 513,884 shares in the company, valued at $4,116,210.84. This trade represents a 2.49% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 3.90% of the company's stock.

ADMA Biologics Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company's marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source